Modality
Radioligand
MOA
PCSK9i
Target
CGRP
Pathway
Checkpoint
MCLNarcolepsy
Development Pipeline
Preclinical
~Sep 2015
→ ~Dec 2016
Phase 1
~Mar 2017
→ ~Jun 2018
Phase 2
Sep 2018
→ Nov 2030
Phase 2Current
NCT08845792
2,934 pts·MCL
2018-09→2027-03·Recruiting
NCT06290967
757 pts·Narcolepsy
2021-12→2030-11·Recruiting
3,691 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-0211mo awayPh3 Readout· MCL
2030-11-074.6y awayPh3 Readout· Narcolepsy
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Recruit…
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-03-02 · 11mo away
MCL
Ph3 Readout
2030-11-07 · 4.6y away
Narcolepsy
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08845792 | Phase 2/3 | MCL | Recruiting | 2934 | Safety |
| NCT06290967 | Phase 2/3 | Narcolepsy | Recruiting | 757 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| MRK-8368 | Merck & Co | Phase 3 | ALK | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| AZN-4015 | AstraZeneca | Preclinical | BCMA | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Polazasiran | Amgen | Phase 2 | LAG-3 | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| INC-1261 | Incyte | Phase 1/2 | PRMT5 |